Expensive cancer drugs: a comparison between the United States and the United Kingdom.
about
Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006.Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales.The economic pressures for biosimilar drug use in cancer medicineComparing UK and 20 Western countries' efficiency in reducing adult (55-74) cancer and total mortality rates 1989-2010: Cause for cautious celebration? A population-based study.Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational studyUK and Twenty Comparable Countries GDP-Expenditure-on-Health 1980-2013: The Historic and Continued Low Priority of UK Health-Related ExpenditureAdvances in cancer therapeutics and patient access to new drugs.Health systems performance and cancer outcomes.Healthcare Systems in Comparative Perspective: Classification, Convergence, Institutions, Inequalities, and Five Missed Turns.Evidence and values: paying for end-of-life drugs in the British NHS.Out of pocket, out of sight? An unmeasured component of the burden of cancer.A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.Valuing end-of-life care in the United States: the case of new cancer drugs.
P2860
Q33756387-36DCB00E-47E6-408F-8C64-C97AA7F5F7CCQ34643295-C6DE1CC6-60B0-40BF-ABC0-2212902EADB6Q35623274-B4CC2300-EBE4-4BE4-B076-E89376E8F9C0Q35678127-52D31373-F86D-49D0-83A5-FC4F7835D544Q35795204-0A6F70A5-B8E7-49E9-B899-363455847123Q36987412-059696B3-46B4-4596-9045-DA833A2B37C3Q37007189-BABF3991-F566-492D-B564-99781B3B7C7DQ37230735-918D9E57-3CD2-4769-97EB-4D77DD92D407Q37823895-F8B79A54-0129-4ACC-AF69-7126EA2DAB13Q38130362-1DF35802-E01F-432A-9913-E2859401231DQ38645828-1FE4A71B-0399-47DB-94A8-0188DD5E5D1FQ39534205-16882945-064E-4CFB-A758-EC5D53B98DD1Q43210863-47BB48D7-28CB-4A7C-9E72-9675D1CB9C63Q44008750-71593CEF-C755-4ADC-8646-EF47AC442A16Q47563275-997A6ED6-BA21-4DB9-851A-7C36F0132277
P2860
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
@ast
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
@en
type
label
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
@ast
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
@en
prefLabel
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
@ast
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
@en
P2093
P2860
P1433
P1476
Expensive cancer drugs: a comparison between the United States and the United Kingdom.
@en
P2093
Hugh R Waters
John Appleby
Jonathon P Leider
Kalipso Chalkidou
P2860
P304
P356
10.1111/J.1468-0009.2009.00579.X
P407
P50
P577
2009-12-01T00:00:00Z